南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

发现苯并呋喃-2-羧酸衍生物作为具有口服疗效的强效PTPRO抑制剂用于治疗炎症性肠病

Discovery of Benzofuran-2-Carboxylic Acid Derivatives as Potent PTPRO Inhibitors with Oral Efficacy for Treatment of Inflammatory Bowel Disease

Xiao Liang, Xue Li, Junxin Xue, Huirui Wang, Huajun Zhao, Zhongcheng Zhao, Xinying Yang, Jintong Du, Ting Dong, Hao Fang, Xuben Hou

Journal:JOURNAL OF MEDICINAL CHEMISTRY

IF:7.3

DOI:10.1021/acs.jmedchem.6c00259

PMID:42046270

Published:2026-04-27

research field:药理学免疫学药物化学药物发现炎症性疾病

Abstract

Emerging evidence implicates PTPRO as a pivotal regulator in inflammatory bowel disease (IBD). Screening a benzofuran-2-carboxylic acid–based library identified a lead PTPRO inhibitor. Structure-guided optimization yielded compound 10j, a potent and selective PTPRO inhibitor (IC50 = 0.54 μM) that suppressed IL-6 via NF-κB pathway modulation in macrophages. Compound 10j exhibited favorable oral bioavailability and, in a murine DSS-induced colitis model, significantly attenuated disease severity, restored colon length, and suppressed IFN-γ and IL-2 levels. Further optimization produced 30k with enhanced potency (IC50 = 0.16 μM) and superior in vivo efficacy accompanied by an improved safety profile. This work establishes benzofuran-2-carboxylic acid derivatives as promising IBD therapeutics, providing a pharmacological tool for phosphatase-targeted immunomodulation.

本文使用的Yeasen产品

购物车
客服
转染试用